Measuring lorazepam levels in adults with catatonia
Part of Brain & nervous system clinical trials.
This trial looks at adults with catatonia (a serious condition that affects movement and speech) and measures blood levels of lorazepam. It may help doctors better understand how the medicine behaves in the body for people receiving treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have catatonia diagnosed using DSM-5 criteria.
- You cannot be pregnant at the time of the study.
- You (or your legal guardian) must be willing to participate.
- You may be asked for blood samples to measure lorazepam levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often catatonic syndrome occurs in adults treated at Basurto Hospital, what other conditions it's linked to, and what happens in the short term. It helps doctors better understand this serious condition.
This study looks at the immune system and genes of children and teens with catatonia. It aims to find out what causes catatonia and may help guide future treatments.
This trial tests if a single dose of lorazepam can prevent delirium (sudden confusion) in newly admitted ICU patients who are at high risk. It aims to keep you from becoming confused or agitated while in the hospital.
This trial tests whether a sleep medication called lormetazepam can improve sleep quality and brain activity in ICU patients who are on a breathing machine. It may help if you need sedation and are expected to stay in the ICU for at least two days.
This study measures brain signals during scans to look for patterns linked to two types (subforms) of psychotic disorders. If you have schizophrenia or schizoaffective disorder and your symptoms have been stable, you may be able to help researchers understand these brain markers.
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
Hear when a new Catatonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.